Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers by unknown
1 3
J Cancer Res Clin Oncol (2016) 142:1927–1946
DOI 10.1007/s00432-016-2195-3
ORIGINAL ARTICLE – CANCER RESEARCH
Decreased expression of connective tissue growth factor 
in non‑small cell lung cancer is associated with clinicopathological 
variables and can be restored by epigenetic modifiers
Hanna Drzewiecka1 · Bartłomiej Gałe˛cki2 · Donata Jarmołowska‑Jurczyszyn3 · 
Andrzej Kluk3 · Wojciech Dyszkiewicz2 · Paweł P. Jagodzin´ski1 
Received: 2 July 2015 / Accepted: 18 June 2016 / Published online: 8 July 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
on NSCLC cells viability and proliferation was monitored 
by the trypan blue assay.
Results We found significantly decreased levels of CTGF 
mRNA and protein (both p < 0.0000001) in cancerous 
tissues of NSCLC patients. Down-regulation of CTGF 
occurred regardless of gender in all histological subtypes 
of NSCLC. Moreover, we showed that 5-dAzaC and TSA 
were able to restore CTGF mRNA and protein contents in 
NSCLC cells. However, no methylation within CTGF regu-
latory region was detected. Both compounds significantly 
reduced NSCLC cells proliferation.
Conclusions Decreased expression of CTGF is a common 
feature in NSCLC; however, it can be restored by the chro-
matin-modifying agents such as 5-dAzaC or TSA and con-
sequently restrain cancer development.
Keywords Connective tissue growth factor (CTGF) · 
Non-small cell lung cancer (NSCLC) · Clinicopathological 
features · Epigenetic regulation · 5-Aza-2′-deoxycytidine 
(5-dAzaC) · Trichostatin A (TSA)
Introduction
Lung cancer (LC) is the most common cancer in the world, 
with more than 1 million cases reported annually (Jemal 
et al. 2011). Due to its high mortality rate, it is also the 
leading cause of cancer-related death worldwide. Two 
major types of LC can be distinguished, basing on clini-
cal classification: non-small cell lung cancer (NSCLC) 
and small cell lung cancer (SCLC). NSCLC is usually 
reported to comprise about 85 % of all lung carcinomas 
and includes the following histological subtypes: adenocar-
cinoma (ADC), squamous cell carcinoma (SCC), large cell 
carcinoma (LCC) and other rare types (Alì et al. 2008).
Abstract 
Purpose Recent studies indicated undisputed contribution 
of connective tissue growth factor (CTGF) in the develop-
ment of many cancers, including non-small cell lung cancer 
(NSCLC). However, the functional role and regulation of 
CTGF expression during tumorigenesis remain elusive. Our 
goal was to determine CTGF transcript and protein levels 
in tumoral and matched control tissues from 98 NSCLC 
patients, to correlate the results with clinicopathological 
features and to investigate whether the CTGF expression 
can be epigenetically regulated in NSCLC.
Methods We used quantitative PCR, Western blotting and 
immunohistochemistry to evaluate CTGF expression in 
lung cancerous and histopathologically unchanged tissues. 
We tested the impact of 5-Aza-2′-deoxycytidine (5-dAzaC) 
and trichostatin A (TSA) on CTGF transcript and protein 
levels in NSCLC cells (A549, Calu-1). DNA methylation 
status of the CTGF regulatory region was evaluated by 
bisulfite sequencing. The influence of 5-dAzaC and TSA 
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Although lung carcinogenesis is one of the most exten-
sively studied disorders, it is a very complex process that 
still requires clarification. In these days, a lot of studies 
focus on the interplay between tumor cells and surrounding 
stromal cells with an extracellular matrix (ECM) that both 
create the tumor microenvironment (Mbeunkui and Johann 
2009; Lu et al. 2012; Sainio and Järveläinen 2014). ECM is 
a complex network of macromolecules and secretory pro-
teins that regulate cell–cell and cell–matrix interactions, 
cellular behavior, as well as tissue polarity and architecture. 
This network is commonly deregulated during malignant 
transformation and plays a crucial role in the tumor devel-
opment and progression (Lu et al. 2012).
Connective tissue growth factor (CTGF) is a 38-kDa, 
cysteine-rich protein belonging to the CCN family (Lau 
and Lam 1999). Biologically active CTGF is widely 
expressed in various cells (e.g., fibroblasts, myofibroblasts, 
endothelial cells, smooth muscle cells and some epithelial 
cell types) and can be secreted to ECM or is located on 
the cell membrane (Chien et al. 2006; Jacobson and Cun-
ningham 2012). Like other members of CCN family, CTGF 
possess multimodular structure which enables binding to 
and interacting with other molecules (Kubota and Takigawa 
2015). Therefore, CTGF as a molecular mediator presents 
pleiotropic functions and plays a pivotal role in a wide vari-
ety of regulatory processes including ECM synthesis and 
rearrangement, wound healing, angiogenesis, cell adhe-
sion, migration, proliferation and differentiation (Cicha and 
Goppelt-Struebe 2009; Ponticos et al. 2009).
So far, diverse studies have indicated variable proper-
ties of CTGF in different tissues, and its expression level 
is thought to be dependent on the cell type and context. A 
lot of cancers present the deregulated expression of CTGF, 
when compared with their normal counterparts, which 
favors tumor growth and progression (Jacobson and Cun-
ningham 2012; Wells et al. 2014). However, the mechanism 
of CTGF action during carcinogenesis may depend on its 
basal level in normal, histopathologically unchanged tissue 
(Wells et al. 2014). An increased expression of CTGF was 
detected in multiple human cancers, e.g., in gliomas, pap-
illary thyroid carcinomas, precursor B-cell acute lympho-
blastic leukemias, hepatocellular carcinoma and malig-
nant melanoma, and was associated with the development 
of those diseases (Braig et al. 2011; Edwards et al. 2011; 
Urtasun et al. 2011; Welch et al. 2013; Wang et al. 2013; 
Finger et al. 2014). On the contrary, this gene was shown to 
be down-regulated in lung and colon cancers and its dimin-
ished expression was correlated with poorer clinical out-
come of patients (Lin et al. 2005; Chen et al. 2007a; Ladwa 
et al. 2011).
Few previous studies showed that the expression of 
CTGF can be epigenetically regulated (Kikuchi et al. 2007; 
Hemmatazad et al. 2009; Komorowsky et al. 2009; Welch 
et al. 2013). The most widely studied epigenetic changes 
in LC include DNA methylation within CpG dinucleo-
tide-rich regions of various genes (CpG islands) and post-
translational modifications of histone tails that affect local 
chromatin architecture (Nelson et al. 2012; Balgkourani-
dou et al. 2013; Heller et al. 2013; Langevin et al. 2015). 
DNA methylation is conducted by DNA methyltransferases 
(DNMTs), and during carcinogenesis, it may lead to hyper-
methylation of the promoter regions of tumor suppres-
sor genes, resulting in their transcriptional silencing, or 
to global hypomethylation that enhances protooncogene 
expression (Luczak and Jagodzin´ski 2006). Histone acety-
lation and the opposite process, deacetylation, are mediated 
by two different sets of enzymes: histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) that alter chro-
matin compaction and thus are involved in transcriptional 
regulation of gene expression (Nervi et al. 2015). To the 
best of our knowledge, there are no reports considering the 
impact of chemical compounds causing chromatin rear-
rangement on the expression level of CTGF in LC.
In the present study, we determined the status of CTGF 
in lung cancerous and corresponding histopathologi-
cally unchanged tissues obtained from 98 patients with 
NSCLC, at both mRNA and protein levels, and we cor-
related them with clinicopathological features. Next, we 
examined the effect of 5-Aza-2′-deoxycytidine (5-dAzaC), 
a well-known DNMTs inhibitor, and trichostatin A (TSA), 
a potent HDACs inhibitor, on the CTGF expression level 
in two NSCLC cell lines belonging to different histologi-
cal subtypes—A549 (ADC) and Calu-1 (SCC). We also 
assessed the impact of those compounds on cell viability 
and proliferation.
Materials and methods
Antibodies and reagents
Goat polyclonal anti-CTGF antibody (Ab) (L-20), rab-
bit polyclonal anti-glyceraldehyde-3-phosphate (GAPDH) 
Ab (FL-335), rabbit anti-goat and goat anti-rabbit horse-
radish peroxidase (HRP)-conjugated Ab were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). TRI 
Reagent®, 5-dAzaC, TSA, dimethyl sulfoxide (DMSO), 
ethanol, fetal bovine serum (FBS), cell culture antibiotics 
and media were provided by Sigma-Aldrich Co. (St. Louis, 
MO).
Patient material
Primary lung cancerous and histopathologically unchanged 
lung tissues, located at least 10–20 cm away from the can-
cerous lesions, were obtained between March 2012 and 
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December 2014 from 98 patients diagnosed with NSCLC, 
who underwent surgical resection at the Department of 
Thoracic Surgery, Poznan University of Medical Sci-
ences, Poland (Tables 1, 2, 3; Supplementary tables 1 and 
2). Among them, 18 patients were never smokers. None of 
the patients received any preoperative chemotherapy and/
or radiation therapy. Histopathological classification was 
performed by an experienced pathologist. After surgical 
removal, tissue samples were immediately snap-frozen 
in liquid nitrogen and stored at −80 °C until further pro-
cessing. All patients participated in this study had signed 
informed consent on the use of clinical specimens, and the 
study was approved by the Local Ethical Committee of 
Poznan University of Medical Sciences.
Cell culture
The human NSCLC cell lines—A549 and Calu-1, breast 
cancer cell line—T47D, and cervical carcinoma cell 
line—HeLa, were purchased from ATCC (Rockville, 
MD). Normal human bronchial epithelial cells—Beas-
2B, were kindly provided by Dr M. Rusin from the Maria 
Skłodowska-Curie Memorial Cancer Center and Insti-
tute of Oncology, Gliwice Branch, Poland. A549, Calu-1 
and T47D cells were routinely maintained in RPMI 1640 
medium, Beas-2B cell line was cultured in DMEM/F12 
medium, and HeLa cell line was maintained in DMEM. 
Cells were grown at 37 °C in humidified air with 5 % CO2. 
All culture media were supplemented with 10 % heat-inac-
tivated FBS, 2 mM glutamine and penicillin–streptomycin–
amphotericin B solution (10,000 U penicillin, 10 mg strep-
tomycin and 25 μg amphotericin B/ml).
NSCLC cell lines treatment with 5‑dAzaC and TSA
The stock solutions of 5-dAzaC (10 mg/ml) and TSA (1 mg/
ml) were prepared in DMSO and ethanol, respectively, ali-
quoted and stored at −20 °C until use. Prior to all experi-
ments, cells were seeded and grown overnight. Next, the 
investigated compounds were diluted in the culture medium 
to the desired concentration and added to cell cultures. The 
same volume of DMSO or ethanol was used as a vehicle 
control, and their final concentration in culture medium 
never exceeded 0.1 %. All experimental media were 
Table 1  Differences in CTGF transcript levels in lung cancerous and corresponding histopathologically unchanged tissues from NSCLC 
patients including clinicopathological characteristic
CTGF transcript levels were standardized by the geometric mean of PBGD and hMRPL19 cDNA levels. Results were expressed as decimal 
logarithm of multiples of cDNA copies in the calibrator. The normality of observed patient data distribution was assessed by Shapiro–Wilk test, 
and parametric unpaired, two-tailed t test was used to compare the mean values. p < 0.05 was considered as statistically significant
Variables Number of cases Cancerous tissues Histopathologically unchanged tissues p value CTGF mRNA
Mean ± SD Mean ± SD
Total no. of patients 98 2.58 ± 0.41 3.12 ± 0.4 <0.0000001
Gender
 Male 63 2.60 ± 0.44 3.08 ± 0.40 <0.0000001
 Female 35 2.54 ± 0.35 3.19 ± 0.38 <0.0000001
Patient age
 ≤60 (males; females) 26 (17; 9) 2.61 ± 0.39 3.16 ± 0.31 <0.000001
 >60 72 (46; 26) 2.57 ± 0.41 3.10 ± 0.42 <0.0000001
Histological type
 Adenocarcinoma (males; females) 39 (22; 17) 2.5 ± 0.33 3.04 ± 0.39 <0.0000001
 Squamous cell carcinoma 48 (36; 12) 2.67 ± 0.44 3.11 ± 0.41 <0.000001
 Large cell carcinoma 5 (3; 2) 2.54 ± 0.33 3.39 ± 0.13 0.0007
 Carcinoid 6 (2; 4) 2.44 ± 0.60 3.46 ± 0.21 0.005
Lung cancer stages
 0 (males; females) 5 (3; 2) 2.45 ± 0.55 3.13 ± 0.50 0.08
 1A 11 (5; 6) 2.70 ± 0.48 3.19 ± 3.33 0.01
 1B 22 (10; 12) 2.52 ± 0.33 2.98 ± 0.34 0.00005
 2A 24 (15; 9) 2.59 ± 0.34 3.17 ± 0.42 0.000004
 2B 16 (13; 3) 2.63 ± 0.39 3.13 ± 0.5 0.003
 3A 19 (16; 3) 2.53 ± 0.52 3.15 ± 0.37 0.0001
 3B – – – –
 4 1 (1; 0) – – –
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exchanged every 24 h. To determine the effect of 5-dAzaC 
on CTGF transcript and protein levels in NSCLC cell lines, 
A549 and Calu-1 cells were cultured for 48, 72 and 96 h 
either in the absence or in the presence of 5-dAzaC at con-
centrations of 10 and 15 μM. In order to evaluate whether 
TSA may regulate CTGF transcript and protein contents 
in A549 and Calu-1 cell lines, cells were treated with dif-
ferent concentrations of TSA (30, 100, 300 nM) or vehicle 
control in a time-dependent manner for 12, 24, 48 and 72 h. 
Each experiment was performed in triplicate, and cells were 
used for protein and RNA isolation, Western blotting and 
RT-qPCR analysis. Additionally, genomic DNA was iso-
lated from cells cultured in the absence or in the presence of 
10 μM 5-dAzaC for 96 h in order to evaluate its impact on 
the methylation status of CTGF regulatory region.
Assessment of A549 and Calu‑1 cells viability 
and proliferation after 5‑dAzaC and TSA treatment 
by a trypan blue staining
A549 and Calu-1 cells were seeded into T-25-cm2 flasks 
and treated with 5-dAzaC or TSA as described above. After 
each incubation period, cells were detached with Trypsin–
EDTA solution, Sigma-Aldrich Co. (St. Louis, MO), centri-
fuged and resuspended in 8 ml of phosphate-buffered saline 
(PBS). Next, cell viability and proliferation were deter-
mined by a trypan blue staining. Fifty μl of cell suspension 
was taken and mixed with the same volume of trypan blue. 
Cells were counted with an EVE™ automatic cell counter, 
NanoEnTek Inc. (Seoul, Korea). For cell viability, results 
are expressed as the percentage of viable cells relative to 
respective controls (100 %), and for cell proliferation, the 
number of counted cells per 1 ml of solution is presented. 
All experiments were performed in triplicate, and data rep-
resent mean ± standard deviation (SD).
Reverse transcription and real‑time quantitative 
polymerase chain reaction (RT‑qPCR) analysis
Total RNA from lung tumors and matched normal lung tis-
sues obtained from the same patients, as well as from inves-
tigated cell lines, was isolated according to the method of 
Chomczyn´ski and Sacchi (1987). RNA samples were quan-
tified and reverse-transcribed into cDNA using M-MLV 
Table 2  Differences in CTGF protein levels in lung cancerous and corresponding histopathologically unchanged tissues from NSCLC patients 
including clinicopathological characteristic
The amount of proteins detected by Western blotting was presented as the decimal logarithm of CTGF-to-GAPDH band optical density ratio. 
The normality of observed patient data distribution was assessed by Shapiro–Wilk test, and parametric unpaired, two-tailed t test was used to 
compare the mean values. p < 0.05 was considered as statistically significant
Variables Number of cases Cancerous tissues Histopathologically unchanged tissues p value CTGF protein
Mean ± SD Mean ± SD
Total no. of patients 98 2.79 ± 0.32 3.06 ± 0.34 <0.0000001
Gender
 Male 63 2.77 ± 0.32 3.11 ± 0.32 <0.0000001
 Female 35 2.8 ± 0.32 3.02 ± 0.39 0.02
Patient age
 ≤60 (males; females) 26 (17; 9) 2.72 ± 0.35 2.85 ± 0.45 0.26
 >60 72 (46; 26) 2.81 ± 0.31 3.16 ± 0.27 <0.0000001
Histological type
 Adenocarcinoma (males; females) 39 (22; 17) 2.72 ± 0.31 3.04 ± 0.43 0.0005
 Squamous cell carcinoma 48 (36; 12) 2.78 ± 0.32 3.08 ± 0.3 0.00001
 Large cell carcinoma 5 (3; 2) 2.89 ± 0.09 3.15 ± 0.16 0.01
 Carcinoid 6 (2; 4) 3.21 ± 0.16 3.2 ± 0.3 0.9
Lung cancer stages
 0 (males; females) 5 (3; 2) 2.98 ± 0.36 3.18 ± 0.54 0.6
 1A 11 (5; 6) 2.91 ± 0.32 3.24 ± 0.18 0.007
 1B 22 (10; 12) 2.71 ± 0.29 3.09 ± 0.28 0.0002
 2A 24 (15; 9) 2.70 ± 0.32 3.04 ± 0.39 0.002
 2B 16 (13; 3) 2.77 ± 0.37 2.87 ± 0.39 0.5
 3A 19 (16; 3) 2.84 ± 0.28 3.18 ± 0.32 0.003
 3B – – – –
 4 1 (1; 0) – – –
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reverse transcriptase from Invitrogen, Life Technologies 
(Grand Island, NY), according to the manufacturer’s pro-
tocol. The RT-qPCR was conducted in a Light Cycler®480 
Real-Time PCR System, Roche Diagnostics GmbH (Man-
nheim, Germany), using SYBR Green I as a detection dye. 
The target cDNA was quantified by relative quantification 
method using a calibrator for primary tissues or respective 
controls for A549 and Calu-1 cells. For the calibrator, 1 µl 
of cDNAs from all tissue samples was mixed together. The 
quantity of CTGF transcript in each sample was standard-
ized by the geometric mean of porphobilinogen deami-
nase (PBGD) and human mitochondrial ribosomal pro-
tein L19 (hMRPL19) cDNA levels. The PCR amplification 
efficiency for target and reference genes was determined 
by the different standard curves, created by consecu-
tive dilutions of the cDNA template mixture, as provided 
in Relative Quantification Manual, Roche Diagnostics 
GmbH (Mannheim, Germany). For amplification, 1 µl of 
total (20 µl) cDNA solution was added to 9 µl of Light 
Cycler®480 SYBR Green I Master mix (1 × concentrated) 
containing 2.5 mM MgCl2 and 0.5 µM primers (Supple-
mentary table 3). A sample of no reverse-transcribed RNA 
and a no-template control were included in each batch of 
samples to provide a negative control in subsequent PCR. 
Melting curve analysis and electrophoresis were applied to 
confirm the specificity of the amplified products. All exper-
iments were performed in triplicate, and CTGF transcript 
levels in investigated tissues were expressed as the decimal 
Table 3  Association between 
CTGF transcript and protein 
levels in lung cancerous tissues 
and different clinicopathological 
parameters
§ t test
# ANOVA
a Post hoc RIR Tukey’s test
‡ Kruskal–Wallis test
Variables Number of cases CTGF mRNA CTGF protein
Mean ± SD p Mean ± SD p
Gender 0.41§ 0.61§
 Male 63 2.60 ± 0.44 2.77 ± 0.32
 Female 35 2.54 ± 0.35 2.80 ± 0.32
Patient age 0.62§ 0.73§
 ≤60 26 2.61 ± 0.39 2.72 ± 0.35
 >60 72 2.57 ± 0.41 2.81 ± 0.31
Histologic type 0.13# 0.047#
 Adenocarcinoma 39 2.49 ± 0.33 2.78 ± 0.29
 Squamous cell carcinoma 48 2.67 ± 0.44 2.83 ± 0.35
 Large cell carcinoma 5 2.43 ± 0.41 2.84 ± 0.32
 Carcinoid 6 2.47 ± 0.54 3.18 ± 0.25 0.026a
Lung cancer stages 0.85# 0.37#
 0–1 38 2.57 ± 0.41 2.89 ± 0.34
 2 40 2.60 ± 0.36 2.79 ± 0.34
 3–4 20 2.52 ± 0.51 2.90 ± 0.29
Tumor size 0.69‡ 0.78#
 Tis–T1 21 2.62 ± 0.47 2.87 ± 0.35
 T2 57 2.56 ± 0.33 2.81 ± 0.34
 T3–T4 20 2.60 ± 0.52 2.82 ± 0.29
Lymph node metastasis 0.09# 0.83#
 N0 54 2.56 ± 0.40 2.78 ± 0.33
 N1 34 2.67 ± 0.40 2.80 ± 0.33
 N2 10 2.35 ± 0.42 2.79 ± 0.26
Distant metastasis 0.23§ 0.58§
 M0 95 2.57 ± 0.41 2.78 ± 0.32
 M1a 3 2.86 ± 0.43 2.80 ± 0.36
Smoking 0.43§ 0.86§
 Yes 80 2.59 ± 0.42 2.83 ± 0.34
 No 18 2.51 ± 0.32 2.82 ± 0.27
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logarithm of multiplicity of cDNA concentrations in the 
calibrator. CTGF transcript levels for A549 and Calu-1 cell 
lines treated with 5-dAzaC or TSA were presented as mul-
tiplicity of the respective controls.
Sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE) and Western blotting 
analysis
Cells were harvested using trypsin–EDTA solution, washed 
twice with PBS and lysed using RIPA lysis buffer, Sigma-
Aldrich Co. (St. Louis, MO). Tissue specimens were 
homogenized in liquid nitrogen and also treated with RIPA 
lysis buffer. In both cases, RIPA buffer was supplemented 
with protease inhibitor cocktail, Roche Diagnostics GmbH 
(Mannheim, Germany). Samples were incubated on ice for 
30 min, with vortexing every 15 min, and then centrifuged 
at 10,000×g for 10 min at 4 °C in order to remove cell 
debris. Supernatant was collected for whole cell lysates. 
The concentration of total protein isolated from cell lines 
was determined by the bicinchoninic acid assay method 
(BCA) using BCA kit from Sigma-Aldrich Co. (St. Louis, 
MO). Next, proteins (30 µg for cell lines) were resuspended 
in a sample loading buffer, boiled at 95 °C for 10 min, 
rapidly cooled on ice and separated on 12 % Tris–glycine 
gel using SDS–PAGE. Gel proteins were transferred to a 
nitrocellulose membrane, which was then blocked with 5 % 
nonfat dry milk in 1× concentrated Tris-buffered saline/
Tween 20 for 2 h at room temperature, on a shaker. After 
blocking, membranes were incubated overnight at 4 °C 
with goat polyclonal anti-CTGF Ab (L-20) at a dilution 
of 1:500, followed by 2-h incubation with rabbit anti-goat 
HRP-conjugated Ab (1:5000). To ensure protein loading 
control of the lanes, membranes were stripped and incu-
bated with rabbit polyclonal anti-GAPDH Ab (FL-335; 
1:3300), followed by incubation with goat anti-rabbit HRP-
conjugated Ab (1:5000). Bands were revealed using Super-
Signal West Femto Chemiluminescent Substrate, Thermo 
Fisher Scientific (Rockford, IL) and Biospectrum® Imag-
ing System 500, UVP Ltd. (Upland, CA). The amounts of 
analyzed proteins were presented as the CTGF-to-GAPDH 
band optical density ratio. For A549 and Calu-1 cells cul-
tured in the absence of 5-dAzaC or TSA, the ratio of CTGF 
to GAPDH was assumed to be 1. Additionally, HeLa cell 
line lysate was used as a positive control for CTGF protein 
identification according to CTGF Ab datasheet.
Immunohistochemistry
Formalin-fixed, paraffin wax-embedded tissue specimens 
were cut on 4-μm sections and mounted on adhesion 
microscope slides SuperFrost®Plus (Menzel Gläser). Next, 
sections were dewaxed and rehydrated, and heat-induced 
antigen retrieval was carried out by cooking in low pH 
EnVision FLEX Target Retrieval Solution, Dako (Glostrup, 
Denmark), for 50 min at 97 °C. Endogenous peroxidase 
was blocked by EnVision FLEX Peroxidase-Blocking 
Reagent, Dako (Glostrup, Denmark), and sections were 
incubated in Novocastra Protein Block, Leica Biosystems 
(Wetzlar, Germany), for 10 min followed by overnight incu-
bation with goat polyclonal anti-CTGF Ab (L-20; dilution 
1:200) in a humid chamber at 4 °C. The primary antibody 
was diluted in EnVision FLEX Antibody Diluent, Dako 
(Glostrup, Denmark). Immunodetection was achieved using 
the LSAB System, Dako (Glostrup, Denmark), which is a 
two-step streptavidin–biotin–HRP method. Each layer was 
incubated for half an hour at room temperature. Between 
each staining steps slides were washed in EnVision FLEX 
Wash Buffer, Dako (Glostrup, Denmark). Visualization was 
achieved using 3-3′-diaminobenzidine tetrachloride (DAB, 
Leica Microsystems). Sections were counterstained with 
Mayer’s hematoxylin, dehydrated, cleared and mounted in 
DPX. Sections from formalin-fixed and paraffin-embedded 
normal human lung were used as positive control. Moreo-
ver, the presence of CTGF staining in histopathologically 
unchanged respiratory epithelium, macrophages and stro-
mal fibroblasts within the tumor sections served as an inter-
nal positive control. Immunohistochemical staining was 
evaluated by experienced pathologist.
Evaluation of DNA methylation status of the CTGF 
CpG‑rich region by bisulfite sequencing and by 
MS‑HRM analysis
The position of CpG islands in the CTGF regulatory region 
was determined by online programs (UCSC Genome Bio-
informatics Site and EMBOSS CpGPlot/CpGReport/
Isochore). Methylation status of 106 CpG islands located 
at Chr6: 132271726–132272591 (according to UCSC 
GRCh37/hg19) was evaluated by sequencing of bisulfite-
modified DNA fragment amplified by following primers 
(Supplementary table 3). Genomic DNA, from A549 and 
Calu-1 cells, cultured in the absence or in the presence of 
10 μM 5-dAzaC for 96 h and from lung cancerous and his-
topathologically unchanged tissues of 98 NSCLC patients, 
was isolated using DNA Mammalian Genomic Purifica-
tion Kit, Sigma-Aldrich Co. (St. Louis, MO). Next, 500 ng 
of genomic DNA was subjected to bisulfite conversion 
according to EZ DNA Methylation Kit™ protocol, Zymo 
Research Corporation (Orange, CA).
Methylation-sensitive high-resolution melting analy-
sis (MS-HRM) was used as a screening method for the 
detection if there are any differences in DNA methylation 
patterns between lung cancerous and histopathologically 
unchanged tissues from NSCLC patients. Methylation 
level of DNA fragment located within the CpG island of 
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CTGF gene was determined by RT-PCR amplification of 
bisulfite-modified DNA, followed by HRM profile analysis. 
The reaction was conducted in a Light Cycler®480 Real-
Time PCR System, Roche Diagnostics GmbH (Mannheim, 
Germany). The CTGF region containing 15 CpG dinucleo-
tides located at Chr6: 132271312–132271581 (according to 
UCSC GRCh37/hg19) was amplified by a pair of primers 
complementary to the bisulfite-DNA-modified sequence 
(Supplementary table 3). For PCR amplification, 1 μl of the 
bisulfite-treated DNA from patients was added to 10 μl of 
5× HOT FIREPol® EvaGreen® HRM Mix, Solis BioDyne 
Co. (Tartu, Estonia) with 0.2 μM primers. Each reaction 
was performed in triplicate. MS-HRM analysis was per-
formed using Light Cycler®480 Gene Scanning software 
and TM Calling software. The methylated and unmethyl-
ated DNA acquires different sequences after bisulfite treat-
ment resulting in different melting profiles of PCR prod-
ucts. We analyzed the shape of achieved melting curves 
among lung cancerous and histopathologically unchanged 
tissues, and when differences were detected, samples were 
targeted for bisulfite sequencing.
For bisulfite sequencing, bisulfite-modified DNA frag-
ment was amplified with FastStart Taq DNA Polymerase 
from Roche Diagnostics GmbH (Mannheim, Germany). 
The PCR products were separated on agarose gel, puri-
fied using Agarose Gel DNA Extraction Kit, Roche (Man-
nheim, Germany), and cloned into pGEM-T Easy Vector 
System I, Promega (Madison, WI). After overnight ligation, 
competent TOPO10 E. coli strain cells were transformed 
with plasmids. Plasmid DNA isolated from five positive 
bacterial clones was used for commercial sequencing. The 
results of bisulfite sequencing were presented using BiQ 
analyzer software and the Bisulfite sequencing Data Pres-
entation and Compilation (BDPC) web server, respectively 
(Bock et al. 2005; Rohde et al. 2009).
Statistical analysis
The normality of the observed patient data distribution was 
assessed by Shapiro–Wilk test. Parametric unpaired, two-
tailed t-test was used to consider statistically significant 
differences of CTGF mRNA and protein levels between 
lung cancerous and histopathologically unchanged tissues 
(p < 0.05). Multivariate regression was performed to detect 
association between histological type of cancer, smoking 
history and CTGF mRNA and protein levels in cancerous 
tissues. Parametric unpaired, two-tailed t-test and ANOVA 
with post hoc RIR Tukey’s test were used to compare nor-
mally distributed variables between groups. Otherwise, 
Kruskal–Wallis test was performed. Data groups for cell 
lines were assessed by ANOVA to evaluate whether there 
was significance (p < 0.05) between the groups. For all 
experimental groups, which fulfilled the initial criteria, 
individual comparisons were made by post hoc Tukey’s 
test with the assumption of two-tailed distribution. Data are 
expressed as the mean ± SD. Statistical analysis was per-
formed with STATISTICA 12 software.
Results
CTGF transcript and protein levels are significantly 
decreased in lung cancerous tissues and are correlated 
with various clinicopathological features of NSCLC 
patients
In the present study, employing RT-qPCR and Western 
blotting, we found significantly lowered levels of CTGF 
transcript (p < 0.0000001) and protein (p < 0.0000001) in 
lung cancerous tissues compared with adjacent histopatho-
logically unchanged tissues obtained from 98 patients with 
NSCLC (Fig. 1a–c). Of the 98 pairs, only 9 pairs (~9 %) 
presented higher amount of CTGF mRNA level in tumor 
tissue, 13 (~13 %) pairs presented higher CTGF protein 
content in cancerous tissue, and in 6 pairs (~6 %), CTGF 
mRNA level did not correspond to the protein level. To 
clarify the clinical significance of CTGF expression in 
NSCLC, we showed the differences in CTGF mRNA and 
protein levels between lung cancerous and histopathologi-
cally unchanged tissues including various clinicopathologi-
cal features (Tables 1, 2; Supplementary tables 1 and 2). A 
substantial decrease in CTGF mRNA levels was detected 
in lung cancerous tissues, regardless of gender (males and 
females: p < 0.0000001), patients age (age ≤ 60 years: 
p < 0.000001; age > 60 years: p < 0.0000001) and his-
tological type of NSCLC (ADC: p < 0.0000001; SCC: 
p < 0.000001; LCC: p = 0.0007; carcinoid: p = 0.005; 
Table 1). Those differences were statistically significant in 
all LC stages except stage 0 (p = 0.08). As shown in sup-
plementary table 1, lowered CTGF transcript levels in lung 
cancerous tissues compared with matched normal speci-
mens were associated with almost all tumor sizes, with 
the exception of Tis and T4 and with all grades of lymph 
node metastasis. Western blotting results showed that sig-
nificantly lower amount of CTGF protein in lung cancerous 
tissues was detected at both genders (males: p < 0.0000001; 
females: p = 0.02) and in ADC (p = 0.005), SCC 
(p = 0.00001) and LCC (p = 0.01) histological subtypes 
of NSCLC (Table 2). Moreover, the decreased amount of 
CTGF protein was associated with T1b (p = 0.02), T2a 
(p = 0.000002) and T3 (p = 0.0007) tumor size and with 
all grades of lymph node metastasis (N0: p = 0.000004; 
N1: p = 0.01; N2: p = 0.03; Supplementary table 2). How-
ever, the difference in CTGF protein level between can-
cerous and histopathologically unchanged tissues did not 
reach statistical significance in the group of patients under 
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60 years of age, in patients with recognized carcinoid and 
with LC stage 0 and 2B (Table 2). We cannot consider the 
association of CTGF expression level with distant metas-
tasis as 95 patients presented no distant metastasis (M0). 
We performed multivariate analysis to investigate the asso-
ciation of CTGF mRNA and protein levels with a history 
of smoking and histological type of LC. All models were 
weak, with an adjusted R2 < 0.7. We did not find a signifi-
cant association of CTGF expression level with smoking 
status. However, we observed that in the group of cancer-
ous tissues CTGF protein level was associated with his-
tological type of LC (p = 0.013). The highest amount of 
CTGF protein was detected in carcinoid tumors and the 
lowest amount in ADCs. We also analyzed the relation-
ship between CTGF transcript and protein levels in can-
cerous tissues and different clinicopathological parameters 
(Table 3). We found that there was significant difference 
in CTGF protein levels among histological types of LC 
(p = 0.047). The amount of CTGF protein was signifi-
cantly decreased in ADCs compared with carcinoid tumors 
(p = 0.026). We did not identify any statistically significant 
difference between CTGF transcript and protein levels and 
other clinicopathological variables such age, sex, LC stage, 
tumor size, lymph node metastasis or smoking (Table 3).
In order to complement our Western blotting results and 
to define the distribution and localization of CTGF protein 
in investigated patients’ material, representative NSCLC 
and non-tumoral lung specimens were immunohistochemi-
cally stained with anti-CTGF Ab (Fig. 2). Positive CTGF 
staining was found in normal lung tissues, with strong 
immunoreactivity in macrophages and in respiratory epi-
thelium (Fig. 2a, b). SCC cells showed no or very weak 
cytoplasmic staining (Fig. 2c, d), whereas ADC cells were 
all negative for CTGF staining (Fig. 2e, f). However, the 
presence of CTGF protein was detected in tumor-infiltrat-
ing macrophages, stromal fibroblasts and normal bronchial 
Fig. 1  CTGF transcript and protein levels in lung cancerous and 
histopathologically unchanged tissues obtained from 98 patients 
with NSCLC. a CTGF transcript levels in NSCLC patients’ tissues. 
Total RNA was reverse-transcribed and cDNAs were studied by RT-
qPCR analysis. Target cDNA was quantified by relative quantifica-
tion method using a calibrator. The amount of CTGF mRNA was 
expressed as the decimal logarithm of multiples of cDNA copies in 
the calibrator. b CTGF protein levels in NSCLC patients’ tissues. Iso-
lated proteins were separated by 12 % SDS-PAGE and detected by 
Western blotting. The band densitometry readings were normalized to 
GAPDH loading control. The amount of CTGF proteins detected in 
tissues was presented as the decimal logarithm of CTGF-to-GAPDH 
band optical density ratio. c Representative picture of Western blot 
analysis in lung cancerous tissues (C) and their matched histopatho-
logically unchanged tissues (N) obtained from patients with NSCLC. 
HeLa cell line lysate was used as a positive control for CTGF protein 
identification. The p value in each graph was evaluated by parametric 
unpaired, two-tailed t test
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epithelial cells located in the tumor field and was used as 
an internal positive control (Fig. 2c–f). Representative 
hematoxylin- and eosin-stained slides are shown in Supple-
mentary figure 1.
Taken together, these results indicate that CTGF expres-
sion is significantly diminished in lung cancerous tissues of 
NSCLC patients; however, its exact role during tumorigen-
esis needs to be further investigated.
Comparison of the basal CTGF expression level 
in NSCLC cells (A549, Calu‑1), Beas‑2B and T47D cell 
lines
Basal expression patterns of CTGF in investigated cells 
were determined by RT-qPCR, and the amount of CTGF 
protein was detected by Western blotting, respectively 
(Fig. 3a). A549 and Calu-1 cells presented definitely low-
ered content of CTGF mRNA in comparison with Beas-
2B cell line. We observed that CTGF mRNA levels were 
about 7.5 times lower in A549 cells and 3.4 times lower 
in Calu-1 cells than in Beas-2B cells. The amounts of 
CTGF protein were consistent with the RT-qPCR results 
(Fig. 3a). However, the content of CTGF transcripts and 
protein in NSCLC cells was higher than in T47D, which 
is known to express CTGF at very low levels (Chen et al. 
2007b). CTGF mRNA and protein levels detected in A549 
cells were reduced more than twofold in comparison with 
those from Calu-1 cells. As expected, these results con-
firmed that the expression level of CTGF in NSCLC cells 
is diminished.
5‑dAzaC increases CTGF transcript and protein levels 
in A549 and Calu‑1 cells
In order to determine whether the expression of CTGF can 
be epigenetically regulated in NSCLC cells, we investi-
gated whether DNMTs inhibition by 5-dAzaC would exert 
any effect on the CTGF mRNA level. After 96 h of incuba-
tion with 5-dAzaC at concentrations of 10 and 15 μM, we 
observed an elevation of CTGF transcript levels in A549 
and Calu-1 cells (Fig. 3b). However, this induction was sta-
tistically significant only for Calu-1 cell line (p < 0.001). 
We noticed an approximately twofold increase in CTGF 
mRNA levels in A549 cells and 2.5-fold increase in Calu-1 
cells. The effect was not dose dependent as both concen-
trations of 5-dAzaC up-regulated CTGF expression to the 
similar level in each cell line. Next, we examined whether 
RT-qPCR results would correspond to CTGF protein 
Fig. 2  Representative immunohistochemical staining of CTGF in 
formalin-fixed, paraffin-embedded clinical tissue specimens. Positive 
immunoreactivity is indicated by the brown staining. Normal lung tis-
sues were used as a positive control. a Normal lung tissue with strong 
CTGF staining detected in macrophages and some alveolar epithelial 
cells. b Moderate CTGF staining in normal respiratory epithelium (in 
normal epithelial cells lining the bronchial airway). c, d Representa-
tive immunohistochemistry images of SCC tissue specimens. SCC 
cells showing weak (c) or negative (d) staining for CTGF are indi-
cated by black arrows. The presence of CTGF staining in normal res-
piratory epithelium (c) and in stromal fibroblasts (d) located within 
SCC tissue specimens served as an internal positive control. e, f Rep-
resentative immunohistochemistry images of ADC specimens with 
indicated ADC cells showing no staining for CTGF (black arrows). 
Positive reaction was restricted to tumor-infiltrating macrophages (e, 
f). Original magnifications ×400 (a, b, c, f) and ×100 (d, e)
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content. The densitometric analysis of Western blotting 
bands revealed that 5-dAzaC (10 μM) was able to raise 
the CTGF protein amount in investigated cells after 72 
and 96 h of incubation as compared to respective controls 
(Fig. 3c). The double bands (36 and 38 kDa) of full length, 
intact CTGF were detected (Zarrinkalam et al. 2003), 
and both were markedly increased after 5-dAzaC treat-
ment. Moreover, we investigated whether the same effect, 
exerted by 5-dAzaC, would be observed in Beas-2B cells. 
We revealed that 5-dAzaC (10 uM) was also able to elevate 
CTGF mRNA and protein levels in Beas-2B cell line after 
48, 72 and 96 h of treatment (Supplementary figure 2).
5‑dAzaC significantly inhibits NSCLC cells 
proliferation without marked reduction in cell viability
To determine whether concentrations of 5-dAzaC used 
in previous experiments do not exert a pronounced cyto-
toxic effect in investigated cell lines, we applied trypan 
blue exclusion assay for the measurement of cell viabil-
ity. We showed that 5-dAzaC at concentrations of 10 and 
15 µM reduced cell viability in a dose-dependent manner 
in both A549 and Calu-1 cell lines. The results were sta-
tistically significant at each time point (Fig. 4a, b). How-
ever, after 48, 72 and 96 h of incubation with 5-dAzaC 
(10 µM), A549 and Calu-1 cell viability was higher than 
90 % compared with respective controls. The second dose 
of 5-dAzaC (15 µM) was more effective in reducing cell 
viability, although the amount of viable A549 and Calu-1 
cells was still not lower than 80 %. On the contrary, both 
concentrations of 5-dAzaC were extremely potent in reduc-
ing the proliferation rate of A549 and Calu-1 cells. The cell 
growth inhibition was statistically significant and occurred 
after 72 h of incubation, for both cell lines, at both con-
centrations of 5-dAzaC (p < 0.001; Fig. 4c, d). Cell num-
ber counting by trypan blue assay revealed that after 96 h, 
5-dAzaC (10 and 15 µM) reduced the proliferation of A549 
cells by approximately 51 and 70 %, respectively (Fig. 4c). 
Both concentrations of investigated compound exhibited 
the same effect in Calu-1 cells at indicated time point, 
Fig. 3  Basal and 5-dAzaC-induced expression of CTGF in NSCLC 
cell lines. a Comparison of the CTGF mRNA and protein abundance 
between NSCLC cells (A549, Calu-1), Beas-2B and T47D cells. 
Cells were cultured for 72 h in an appropriate medium and then were 
used for total RNA and protein isolation. CTGF cDNA levels were 
determined by RT-qPCR. Each sample was determined in tripli-
cate, and results represent mean ± SD from three experiments. Iso-
lated proteins were separated by 12 % SDS-PAGE and detected by 
Western blotting. The band densitometry readings were normalized 
to GAPDH loading control. The ratio of CTGF to GAPDH protein 
for Beas-2B cells was assumed to be 1. b 5-dAzaC increases CTGF 
transcript levels in A549 and Calu-1 cells. Cells were cultured for 
96 h in the absence or in the presence of 5-dAzaC (10 and 15 μM). 
Next, cells were used for total RNA isolation and RT-qPCR analysis. 
CTGF transcript levels are presented as multiplicity of the respective 
controls. Each sample was determined in triplicate and results repre-
sent mean ± SD from three experiments (**p < 0.001). c 5-dAzaC 
increases CTGF protein level in A549 and Calu-1 cells. Cells were 
cultured for 48, 72 and 96 h in the absence or in the presence of 
5-dAzaC (10 μM). Next, 30 μg of protein isolated from each sample 
was separated by 12 % SDS-PAGE and detected by Western blotting. 
The band densitometry readings were normalized to GAPDH loading 
control. The ratio of CTGF to GAPDH protein for cells incubated in 
the absence of 5-dAzaC for each period of time was assumed to be 1
▸
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diminishing the proliferation rate by 54 % compared with 
untreated controls (Fig. 4d).
DNA methylation status of CTGF regulatory region 
in A549, Calu‑1 and Beas‑2B cell lines and in lung 
cancerous and histopathologically unchanged tissues 
from patients with NSCLC
Because 5-dAzaC was able to up-regulate CTGF mRNA 
and protein levels in A549, Calu-1 and Beas-2B cells, we 
decided to investigate whether those changes were caused 
by direct demethylation of the CTGF CpG-rich regulatory 
region. For that purpose, we incubated cells either in the 
absence or in the presence of 5-dAzaC (10 µM) for 96 h 
and then we examined the methylation status of 106 CpG 
islands within CTGF regulatory region (Chr6: 132271726–
132272591) by bisulfite sequencing. Surprisingly, for both 
A549 and Calu-1 cells, no methylation in investigated 
region was detected (Fig. 5). The same result was obtained 
for Beas-2B cell line (Supplementary figure 3). These data 
suggest that 5-dAzaC is able to restore CTGF expression in 
NSCLC cells and in normal bronchial epithelial cells; how-
ever, it does not act through direct demethylation of CTGF 
regulatory region. We also evaluated the DNA methylation 
status of CTGF in lung cancerous and in matched normal 
tissues from 28 patients with NSCLC. We used MS-HRM 
analysis as a screening method in order to detect whether 
there are any differences in methylation status in CTGF 
regulatory region between lung cancerous and matched 
normal tissues in the group of 98 patients. We found 56 
matched samples with different melting profiles of PCR 
products (Supplementary figure 4), and we further ana-
lyzed them by bisulfite sequencing. We detected different 
patterns of DNA methylation in examined region (Chr6: 
132271726–132272591) between histopathologically 
unchanged tissues and lung cancerous tissues in the group 
of 28 NSCLC patients (Fig. 6a, b). Among those patients, 
16 had SCC, 9 had ADC, 2 had LCC and 1 was diagnosed 
with carcinoid tumor. Changes in DNA methylation pat-
terns between normal and cancerous tissues were not sta-
tistically significant (p = 0.08); however, this result is pre-
liminary and further studies, on the larger group of patients, 
Fig. 4  Effect of 5-dAzaC treatment on NSCLC cells viability and 
proliferation. Dose–response and time–course analysis of A549 and 
Calu-1 cell viability (a, b) and proliferation (c, d) after 5-dAzaC 
treatment. Cells were incubated in medium either in the absence or 
in the presence of 5-dAzaC at concentrations of 10 and 15 μM for 
48, 72 and 96 h. After incubation, cell viability and proliferation were 
determined by a trypan blue exclusion assay. Cell viability results 
are expressed as a percentage of viable cells compared with respec-
tive untreated controls (100 %). For cell proliferation, the number 
of counted cells/ml is presented. All experiments were performed in 
triplicate, and results represent mean ± SD. Statistical significance: 
*p < 0.05; **p < 0.001 versus corresponding control
1938 J Cancer Res Clin Oncol (2016) 142:1927–1946
1 3
are needed to estimate whether DNA methylation plays any 
role in CTGF silencing in NSCLC.
The effect of TSA on A549 and Calu‑1 cell viability 
and proliferation
Next, we investigated whether other epigenetic mecha-
nism—histone acetylation, could restore the expression 
of CTGF in NSCLC cell lines. We chose one of the most 
potent HDACs inhibitor—TSA, and tested its impact on 
A549 and Calu-1 cell viability and proliferation, in order 
to estimate appropriate concentrations for further experi-
ments. Different doses of TSA (30, 100, 300 and 900 nM) 
were applied to cell cultures for 12, 24, 48 and 72 h, and 
cell viability was evaluated by trypan blue staining and 
compared with ethanol-treated controls. Treatment with 
900 nM of TSA markedly decreased A549 cell viability 
(41 % of controls after 48 h and 24 % of controls after 
72 h) as well as Calu-1 cell viability (77 % of controls after 
48 h and 53 % of controls after 72 h), and this concentra-
tion was excluded from further analysis (Fig. 7a, b). More-
over, we observed that A549 cell line is more vulnerable to 
TSA as significant cell morphology changes were detected 
after exposure to 900 nM of this compound. Other doses of 
TSA did not reduce cell viability to such extent and were 
used in other experiments. After 72 h of incubation with 
300 nM of TSA, A549 cell viability was higher than 55 % 
and Calu-1 cell viability was higher than 80 % (Fig. 7a, b). 
Moreover, TSA appeared to be a highly potent inhibitor of 
NSCLC cells proliferation. The growth rate of A549 and 
Calu-1 cells after TSA treatment was significantly dimin-
ished in a dose and time-dependent manner compared with 
respective controls (Fig. 7c, d).
TSA increases CTGF transcript and protein levels 
in A549 and Calu‑1 cells
 We showed that TSA is able to regulate the expression 
of CTGF in A549 and Calu-1 cells. After treatment with 
increasing doses of TSA, we observed a progressive eleva-
tion of CTGF transcript levels in A549 cell line at each 
time point (Fig. 8a). Although the upward trend was visible 
for each concentration of TSA, statistically significant dif-
ferences in CTGF mRNA levels between A549 treated and 
control cells were detected at 300 nM of TSA (p < 0.001; 
Fig. 8a). On the contrary, in Calu-1 cells only the high-
est tested dose of TSA (300 nM) resulted in an increase 
in CTGF transcript levels at each time of incubation 
(p < 0.001; Fig. 8b). Changes in CTGF transcript levels, 
induced by TSA, in both NSCLC cell lines were correlated 
with an elevation of CTGF protein amount (Fig. 7c, d). The 
densitometric analysis of Western blotting bands showed 
a progressive increase in CTGF protein levels after TSA 
treatment in A549 cells, in a dose-dependent manner at 12, 
24, 48 and 72 h of incubation (Fig. 8c). The CTGF protein 
content in Calu-1 cells incubated with 300 nM of TSA was 
significantly elevated as compared to the respective con-
trols at each time of incubation (Fig. 8d). Taken together, 
we showed that although A549 and Calu-1 cells vary in 
the sensitivity to TSA, this compound is able to restore the 
expression level of CTGF in those cell lines.
Discussion
There are a lot of contradictory data describing the role of 
CTGF during carcinogenesis. However, the differences in 
Fig. 5  DNA methylation assessment of CTGF regulatory region by 
bisulfite sequencing in A549 and Calu-1 cell lines. A549 and Calu-1 
cancer cells were cultured for 96 h either in the absence or in the 
presence of 5-dAzaC at a concentration of 10 μM. Then, cells were 
used for genomic DNA isolation, followed by bisulfite conversion of 
cytosine to uracil. The CpG-rich region containing 106 CpG dinucle-
otides was then amplified by a pair of primers complementary to the 
bisulfite-DNA-modified sequence (Supplementary table 3). The PCR 
products were purified with subsequent cloning into a plasmid vector. 
Plasmid DNA isolated from five bacterial clones was used for com-
mercial sequencing. The results of bisulfite sequencing were assessed 
and presented using BiQ analyzer software and BDPC web server. 
Gray boxes represent unmethylated CpG dinucleotides
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CTGF action seem to be dependent on its basal expression 
level in original, non-tumoral cells. It has been reported that 
this growth factor enhances tumor development, when it is 
over-expressed in cancer cells compared with adjacent nor-
mal cells, or that it inhibits the proliferation and metastasis, 
when its expression pattern is restored in low-expressing 
cancer cells compared with non-transformed counterparts 
(Wells et al. 2014). Besides, the amount of CTGF mRNA 
and protein may change in cancerous tissue during tumor 
development, and it is not known whether this is a growth 
advantage for cancer cells or rather the reaction from stro-
mal cells in order to inhibit the proliferation and metastasis 
(Kikuchi et al. 2007). Therefore, CTGF being expressed 
by cancer cells or surrounding stromal cells became an 
Fig. 6  DNA methylation assessment of CTGF regulatory region 
by bisulfite sequencing in tissue samples obtained from 28 NSCLC 
patients. a Histopathologically unchanged tissues and b lung cancer-
ous tissues obtained from 28 NSCLC patients were used for genomic 
DNA isolation, followed by its bisulfite conversion. a, b The CpG-
rich region containing 106 CpG dinucleotides was then amplified 
by a pair of primers complementary to the bisulfite-DNA-modified 
sequence (Supplementary table 3). The PCR products were purified 
with subsequent cloning into a plasmid vector. Plasmid DNA isolated 
from five bacterial clones was used for commercial sequencing. The 
results of bisulfite sequencing were assessed and presented using BiQ 
analyzer software and BDPC web server. Black and gray boxes rep-
resent methylated and unmethylated CpG dinucleotide, respectively. 
White boxes correspond to undetermined CpG dinucleotides
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important player in the tumor microenvironment and in 
the bidirectional communication between cells (Capparelli 
et al. 2012). The dual nature of this growth factor is empha-
sized by the consequences of its deregulation in various 
cancers. An elevated expression of CTGF has been corre-
lated with more advanced disease and worse survival out-
comes in breast, gastric, esophageal and thyroid cancers as 
well as in gliomas, whereas significantly lowered level of 
CTGF protein has been detected in advanced, poorly dif-
ferentiated colorectal tumors, in nasopharyngeal carcinoma 
and in NSCLCs and was associated with poor prognosis 
(Chang et al. 2004; Lin et al. 2005; Chen et al. 2007a; Liu 
et al. 2008; Zhou et al. 2009; Cui et al. 2011; Edwards et al. 
2011; Zhen et al. 2013; Zhu et al. 2015).
In the present study, we demonstrated significantly low-
ered levels of CTGF transcript and protein in NSCLC cell 
lines (A549, Calu-1) and in lung cancerous tissues obtained 
from 98 patients with NSCLC. These data are consistent 
with the results of previous studies, showing that reduced 
expression of CTGF occurs in NSCLC (Chang et al. 2004; 
Chien et al. 2006; Chen et al. 2007a). We found lower 
levels of CTGF mRNA and protein in A549 cells than in 
Calu-1 cells. This in part reflects the findings of Chang 
et al. (2004) who reported that A549 cell line, as the most 
Fig. 6  continued
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invasive among other investigated ADC cells, express 
a very low or even undetectable level of CTGF protein. 
The authors concluded that CTGF expression is inversely 
associated with an invasive phenotype of lung ADC cells. 
Nonetheless, both A549 and Calu-1 cell lines are charac-
terized as highly invasive and Calu-1 was shown to pos-
sess greater invasive capability (Kumarswamy et al. 2012). 
Therefore, we cannot draw the same conclusion; however, 
it is important to notice that those cells belong to different 
histological subtypes of NSCLC.
In our work, we used both Western blot and immuno-
histochemistry techniques to establish the amount of CTGF 
protein in investigated patients’ specimens, while earlier 
studies performed immunohistochemical staining alone 
(Chang et al. 2004; Chien et al. 2006; Chen et al. 2007a). 
Our results are consistent with those previously described, 
as in analyzed specimens we did not detect CTGF protein in 
ADC cells and SCC cells presented no or only weak cyto-
plasmic staining pattern. However, the same as Chang et al. 
we found strong CTGF immunoreactivity in macrophages, 
stromal fibroblast and normal epithelial cells located within 
the tumor field. This may explain Western blot results, 
where in cancerous tissues we were able to detect CTGF 
protein. It is not know how the presence of this protein in 
tumor-infiltrating macrophages and stromal fibroblasts may 
influence the development of NSCLC. In high-grade serous 
ovarian tumors, where CTGF promotes migration and peri-
toneal adhesion of cancer cells, high amount of CTGF pro-
tein was detected in cancer-related stroma compared with 
matched cancer epithelial cells, whereas in breast cancer, 
high expression of CTGF in tumor cells but not in stromal 
cells had significant clinical relevance (Moran-Jones et al. 
2015; Zhu et al. 2015).
Although Chang et al. (2004) found that lowered CTGF 
protein content was significantly associated with a higher 
grade of lymph node metastasis, larger tumor size and more 
advanced stage of cancer, we were not able to note this in 
our study. Perhaps that is because we did not divide patients 
into groups with lower or higher grade of CTGF expression 
in cancerous tissues. However, using RT-qPCR, Western 
Fig. 7  Effect of TSA treatment on NSCLC cells viability and prolif-
eration. Dose–response and time–course analysis of A549 and Calu-1 
cell viability (a, b) and proliferation (c, d) after TSA treatment. Cells 
were incubated for 12, 24, 48 and 72 h either in the absence or in 
the presence of TSA at concentrations of 30, 100, 300 and 900 nM. 
After incubation, cell viability and proliferation were determined by 
a trypan blue exclusion assay. Cell viability results were expressed as 
a percentage of viable cells compared to respective untreated controls 
(100 %). For cell proliferation, the number of counted cells/ml was 
presented. All experiments were performed in triplicate, and results 
represent mean ± SD. Statistical significance: *p < 0.05; **p < 0.001 
versus corresponding control
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Fig. 8  TSA increases CTGF transcript and protein contents in 
NSCLC cell lines. a, b An increment of CTGF transcript levels in 
A549 and Calu-1 cells after TSA treatment. Cells were cultured from 
12 to 72 h either in the absence or in the presence of TSA at con-
centrations of 30, 100 and 300 nM. Next, cells were used for total 
RNA isolation and RT-qPCR analysis. CTGF transcript levels were 
presented as multiplicity of the respective controls. Each sample was 
determined in triplicate, and results represent mean ± SD from three 
experiments. Statistical significance: *p < 0.05; **p < 0.001 versus 
corresponding control. c, d TSA increases CTGF protein levels in 
A549 and Calu-1 cells. Cells were cultured from 12 to 72 h either in 
the absence or in the presence of TSA at concentrations of 30, 100 
and 300 nM. Next, 30 μg of protein isolated from each sample was 
separated by 12 % SDS-PAGE and detected by Western blotting. The 
band densitometry readings were normalized to GAPDH loading con-
trol. The ratio of CTGF to GAPDH protein for cells incubated in the 
absence of TSA for each period of time was assumed to be 1
1943J Cancer Res Clin Oncol (2016) 142:1927–1946 
1 3
blotting and immunohistochemistry we demonstrated 
that the great majority of NSCLC tumors express signifi-
cantly lower levels of CTGF than paired normal lung tis-
sues, and this phenomenon is correlated with various clin-
icopathological features. Even if the differences in CTGF 
mRNA and protein amounts between investigated tissues 
did not reach statistical significance among some groups, 
the decline trend in cancerous specimens was sustained. 
Moreover, we showed that the amount of CTGF protein in 
cancerous tissue is associated with histological type of LC, 
with the lowest content in ADC. Therefore, those results 
highlight the need to identify what role does CTGF play in 
NSCLC development.
The involvement of this growth factor in angiogenesis 
and in the metastatic phenotype of various malignancies is 
crucial and however still remains elusive. Yang and cow-
orkers pinpointed CTGF as a major angiogenic inducer in 
prostate stromal cells. An elevated expression of CTGF in 
carcinoma-associated reactive stroma promoted the growth 
of LNCaP cells and increased microvessel density in nude 
mice (Yang et al. 2005). Furthermore, CTGF promoted 
the growth, motility and migration of glioblastoma mul-
tiforme cells, stimulated neovascularization and enhanced 
the ability of those cells to form tumors in mice (Yin et al. 
2010). The amount of secreted and cell-associated CTGF 
protein was substantially increased in breast cancer cells 
exposed to hypoxic conditions, and CTGF was shown to 
be involved in the regulation of matrix metalloproteinases 
(MMPs) as well as their tissue inhibitors (TIMPs; Shimo 
et al. 2001; Kondo et al. 2002). The authors concluded that 
CTGF is the major factor promoting angiogenesis in vitro 
and in vivo and contributing to the invasion of breast can-
cer cells (Kondo et al. 2002). Accordingly, knockdown of 
CTGF expression significantly decreased the migration 
and an invasion rate of gastric cancer cell lines via reduc-
tion of MMPs expression level (Jiang et al. 2011). Further 
studies are needed to determine the impact of CTGF on 
MMPs and TIMPs expression and on the ECM rearrange-
ment in NSCLC. On the contrary, CTGF was shown to 
bind the most abundant variant of vascular endothelial 
growth factor—VEGF 165, and thus inhibits its angio-
genic properties (Inoki et al. 2002; Hashimoto et al. 2002). 
Forced expression of CTGF significantly lowered VEGF 
mRNA and protein levels in NSCLC cell lines and inhib-
ited their invasion and metastasis in mouse xenograft 
tumor model (Chang et al. 2006). Further experiments 
indicated that CTGF exerts an anti-angiogenic effect in 
NSCLC by the reduction of hypoxia-inducible factor 1α 
(HIF-1α) protein stability (Chang et al. 2006). HIF-1α is 
recognized as a main transcription factor regulating VEGF 
expression (Ziello et al. 2007). During our work, we also 
observed the decreased HIF-1α protein amount in NSCLC 
cells, after an elevation of CTGF expression by TSA and 
5-dAzaC treatment (data not shown). However, this was 
rather due to the destabilizing effect of those compounds 
on HIF-1α protein than the influence of CTGF itself 
(Liang et al. 2006). The development of solid tumors is 
often accompanied by hypoxic conditions that result in the 
accumulation of HIF-1α, which alters gene transcription, 
enhancing glucose uptake, glycolysis, oxygen transport 
and angiogenesis (Webb et al. 2009). Therefore, an eleva-
tion of the CTGF expression could be of benefit at least in 
NSCLC, as in other malignancies CTGF was shown to be 
a hypoxia-responsive gene leading to an enhancement of 
cancer cells invasion (Kondo et al. 2002, 2006; Braig et al. 
2011; Eguchi et al. 2013).
The results of our work show that the expression of 
CTGF in NSCLC can be epigenetically regulated. Incuba-
tion of A549 and Calu-1 cells with 5-dAzaC or with TSA 
significantly increased CTGF mRNA and protein levels. 
The same effect was observed for Beas-2B cells. Previ-
ously, several studies have also established the role of 
epigenetic mechanisms in the regulation of CTGF expres-
sion in other cancers. Disturbances of the DNA methyla-
tion pattern within CpG islands of CTGF led to its aber-
rant expression in ovarian cancer and in precursor B-cell 
acute lymphoblastic leukemias (Kikuchi et al. 2007; Welch 
et al. 2013). Additionally, the transcription of CTGF was 
shown to be regulated by TSA in mouse renal cells and in 
skin fibroblasts obtained from patients with systemic scle-
rosis (Hemmatazad et al. 2009; Komorowsky et al. 2009). 
The epigenetic regulation of CTGF was also determined 
in hepatomas (Chiba et al. 2004). However, to the best of 
our knowledge, this is the first report indicating 5-dAzaC 
and TSA-induced over-expression of CTGF in NSCLC 
cells, although our findings suggest that 5-dAzaC induces 
the expression of CTGF in A549, Calu-1 and Beas-2B cells 
without altering the methylation status of its regulatory 
region. So, the mechanism of action is indirect and differ-
ent than presented in ovarian cancer cell lines and tissues, 
where loss of CTGF expression was caused by hypermeth-
ylation of CpG islands and restored by 5-dAzaC (Kikuchi 
et al. 2007). Moreover, treatment of ovarian cancer cell 
lines with TSA alone had no effect on the expression level 
of CTGF, whereas in A549 and Calu-1 cells it significantly 
induced CTGF mRNA and protein content, suggesting that 
down-regulation of this gene in NSCLC cells and in ovar-
ian cancer cells has distinct molecular basis. CTGF was 
identified as a functional target of several transcription 
factors and micro-RNAs which expression can be either 
epigenetically regulated (Chowdhury and Chaqour 2004; 
Chuang and Jones 2007; Komorowsky et al. 2009; Kubota 
and Takigawa 2015; Tian et al. 2015; Guo et al. 2015). 
Therefore, mechanisms other than direct DNA methylation 
in the regulatory region of CTGF may be responsible for its 
silencing in NSCLC cell lines.
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Nonetheless, in our study we determined that the aber-
rant methylation of CTGF occurs in NSCLC tumors com-
pared with histopathologically unchanged tissues. Although 
results were not statistically significant, we performed 
preliminary analysis for the presence of transcription fac-
tors binding sites in our CTGF regulatory sequence using 
JASPAR database and we found potential binding sites 
for several transcription factors (HES7, ZIC4; SP8, SP2) 
(Mathelier et al. 2015). However, their role in the regula-
tion of CTGF expression in NSCLC needs to be investi-
gated and the precise mechanisms by which 5-dAzaC and 
TSA induce the expression of CTGF in NSCLC cells need 
to be further established.
An application of tested compounds (5-dAzaC and TSA) 
could be of benefit in NSCLC, at least for two reasons: not 
only they increased the amount of CTGF transcripts and 
protein in NSCLC cell lines, but they also contributed to 
the reduction in cell proliferation. Cheng et al. (2004, 
2006) reported that an elevated expression level of CTGF 
correlates with lower invasive and metastatic ability of lung 
ADC cells, in vitro and in vivo, in a mouse model. None-
theless, it did not disturb the growth of those cells (Chang 
et al. 2004). However, another study by Chien et al. (2006) 
revealed that both an over-expression of CTGF or treatment 
with purified CTGF protein suppressed the growth of SCC 
and LCC cells. This raised the question whether CTGF 
actions are related to the specific histological subtype of 
NSCLC.
In the present study, we showed that both 5-dAzaC and 
TSA were able to reduce NSCLC cells proliferation in a 
p53-independent manner, as A549 cells possess a wild-type 
TP53 and both alleles of TP53 are deleted in Calu-1 cells. 
These results are consistent with previous findings. In mel-
anoma cells, TSA was reported to induce growth arrest and 
apoptosis without the involvement of p53 protein (Peltonen 
et al. 2005) and several lines of evidence have indicated 
that both wild-type and TP53-deficient cells are very sensi-
tive to 5-dAzaC (Nieto et al. 2004; Liu et al. 2012).
The potent antitumor activity of TSA against NSCLC 
cells was confirmed by Mukhopadhyay and coworkers. TSA 
evoked a tenfold greater growth inhibition of NSCLC cell 
lines in comparison with normal lung fibroblasts (Mukho-
padhyay et al. 2006). Moreover, it is known that TSA pre-
sents a greater specificity for cancer cells (compared with 
normal counterparts) than other HDAC inhibitors (Chang 
et al. 2012). This feature allows it to be applied at low and 
apparently non-toxic doses. Indeed, we did not observe 
the cytotoxic effect of TSA on A549 and Calu-1 cells at an 
investigated range of concentrations (30–300 nM). Because 
the reactivation of silenced genes expression by DNMTs 
inhibitors may open the way for new treatment strategies, 
5-dAzaC has been extensively studied in NSCLC with 
promising results (Momparler 2013). In our work, we 
showed that 5-dAzaC at concentrations of 10 and 15 µM 
was able to inhibit A549 and Calu-1 cells proliferation with-
out the significant reduction in cell viability.
In conclusion, our study demonstrates that CTGF tran-
script and protein levels in lung cancerous tissues from 
NSCLC patients are significantly reduced compared with 
matched normal control specimens and that the expression 
of CTGF in NSCLC can be epigenetically regulated and 
restored. Further studies are needed to determine whether 
CTGF targeting would be of benefit during NSCLC 
therapy.
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